Dr. Mohyeddin Assali and Dr. Naim Kittana from the Faculty of Medicine and Health Sciences at An-Najah National University joined a groundbreaking research project led by key scientists from Leibniz Research Centre for Working Environment and Human Factors Technical University Dortmund, Germany. They developed a novel way to treat cholemic nephropathy, which is a rare but serious kidney disease caused by bile acid accumulation. The study was published in the Journal of Hepatology, which is a prestigious journal in this field with an impact factor of 25.7.

The researchers discovered that the apical sodium-dependent bile acid transporter (ASBT), a protein that transports bile acids from the urine into the kidney cells, is the main culprit for cholemic nephropathy. They blocked ASBT with a specially designed compound, named AS0369, and prevented bile acid overload in the kidney cells. As a result, they reversed the signs of cholemic nephropathy in a mouse model. AS0369 is the first drug that targets ASBT in the kidneys. It has a high specificity and selectivity for ASBT, meaning that it does not affect other bile acid transporters in the body. The researchers hope that AS0369 can be developed into a safe and effective treatment for patients with cholemic nephropathy.

Link of the study:


عدد القراءات: 26